Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06463171

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Phase II Clinical Study of Almonertinib in Combination With Lastet in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR Mutations

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Conditions Lung Cancer Non-small Cell Stage IV

Interventions Almonertinib

Updated 2 times since 2024 Last updated: Jun 14, 2024 Started: Jun 30, 2024 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Cancer Non-small Cell Stage IV, this trial is actively recruiting participants. The trial is conducted by Shanghai Pulmonary Hospital, Shanghai, China and has accumulated 2 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Pulmonary Hospital, Shanghai, China
Shanghai Zhongshan Hospital
The First Affiliated Hospital of Xiamen University

Data source: Shanghai Pulmonary Hospital, Shanghai, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China
• Xiamen, China